Immune Checkpoint Cellular Assays

InvivoGen has developed cellular assays to investigate immune checkpoint (IC) modulation.

These assays were specifically designed to provide a biologically relevant, sensitive, and well-controlled alternative to the use of primary human T cells for antagonist or agonist screening of the:

Principle of IC cellular assays
(click to enlarge)

– PD-1/PD-L1 axis
– ICOS/ICOS-L axis

Depending on your research needs, you may choose from:

• Jurkat-Raji PD-1/PD-L1 Bio-IC™:
  A pair of cell lines for the screening of PD-1 or PD-L1 antagonists
• Jurkat-Raji ICOS/ICOS-L Bio-IC™:
  A pair of cell lines for the screening of ICOS or ICOS-L antagonists
• Jurkat-Lucia™ hICOS:
  A single effector cell line for the screening of ICOS agonists

 

Applications

• Screening of IC antagonists:
  The Bio-IC™ paired cell lines allow the mimicking of the immune synapse between T cells and antigen-presenting cells through the interaction of cell surface molecules delivering T cell activation and concomitant inhibitory checkpoint signals. In the presence of a potent IC antagonist, there is Lucia production.
• Screening of IC agonists:
  The single effector cell line assay features the surface expression of an activatory IC receptor and CD3ζ chain fusion protein. The engagement of the fusion protein drives T-cell activation. In the presence of a potent IC agonist, there is Lucia production.

 

Assay principle

These assays rely on the monitored activation of T cells, which derive from the human Jurkat-Lucia™ NFAT reporter cell line. They stably express the Lucia luciferase reporter gene under the control of an ISG54 minimal promoter fused to six NFAT response elements. Activation of these cells is measured as a Lucia bioluminescent signal using the appropriate detection reagent QUANTI-Luc™ 4 Lucia/Gaussia.

 

Learn more about immune checkpoints.